PDLIM3 and prostate carcinoma: Numerous studies have reported abnormal expression of PDLIM3 across various cancers, including its upregulation in gastric cancer [19], colon cancer [36], and the SHH subgroup of medulloblastoma [18], while significant downregulation has been found in prostate cancer [20].